Literature DB >> 2043298

Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension.

W H Sheu1, A L Swislocki, B Hoffman, Y D Chen, G M Reaven.   

Abstract

Various aspects of carbohydrate and lipid metabolism have been studied in two groups of patients with mild hypertension before and after four months of treatment with either nifedipine (n = 12) or atenolol (n = 12). Mean (+/- SEM) blood pressure fell to the same degree following treatment with either nifedipine (147 +/- 3/98 +/- 2 to 134 +/- 2/85 +/- 2 mm Hg) or atenolol (149 +/- 3/99 +/- 2 to 135 +/- 2/86 +/- 3 mm Hg). Circulating plasma glucose, insulin, and triglyceride concentrations were measured at hourly intervals from 8:00 AM to 4:00 PM, before and after breakfast (8:00 AM), and at lunch time (noon). The response to treatment was different in the two groups. Specifically, plasma glucose concentration were unchanged and insulin concentrations were higher in association with atenolol treatment. In contrast, nifedipine-treated patients had similar plasma insulin, but lower plasma glucose and triglyceride concentrations after four months of therapy. The changes in day-long plasma glucose and insulin responses suggested that resistance to insulin-stimulated glucose uptake had increased in association with atenolol treatment and decreased following nifedipine. This conclusion was supported in that measurement of insulin-stimulated glucose disposal showed a decrease in atenolol-treated patients and an increase in nifedipine-treated patients. Finally, plasma lipoprotein cholesterol concentrations did not change following atenolol therapy, whereas plasma high density lipoprotein cholesterol increased in association with nifedipine administration. These data show that changes in carbohydrate and lipid metabolism observed with treatment of mild hypertension can vary significantly as a function of the drug used, despite similar beneficial effects on blood pressure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043298     DOI: 10.1093/ajh/4.3.199

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

Review 1.  Antihypertensive drugs and glucose metabolism.

Authors:  Christos V Rizos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2014-07-26

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.

Authors:  R J Milne; S Vander Hoorn; R T Jackson
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 4.  Choosing the correct drug for the individual hypertensive patient.

Authors:  L H Opie
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 5.  Individualised selection of antihypertensive therapy.

Authors:  L H Opie
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension.

Authors:  M Maccario; S E Oleandri; E Avogadri; R Rossetto; S Grottoli; M Procopio; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

7.  A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.

Authors:  James A Timmons; Andrew Anighoro; Robert J Brogan; Jack Stahl; Claes Wahlestedt; David Gordon Farquhar; Jake Taylor-King; Claude-Henry Volmar; William E Kraus; Stuart M Phillips
Journal:  Elife       Date:  2022-01-17       Impact factor: 8.713

8.  Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension.

Authors:  Yuji Shimizu; Fumiyasu Yamasaki; Takashi Furuno; Toru Kubo; Takayuki Sato; Yoshinori Doi; Tetsuro Sugiura
Journal:  Int J Gen Med       Date:  2012-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.